Last: | $17.89 |
---|---|
Change Percent: | 0.06% |
Open: | $17.86 |
Close: | $17.89 |
High: | $17.935 |
Low: | $17.795 |
Volume: | 458,755 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$17.89 | $17.86 | $17.89 | $17.935 | $17.795 | 458,755 | 05-03-2024 |
$17.87 | $17.5 | $17.87 | $17.95 | $17.48 | 765,866 | 05-02-2024 |
$17.51 | $17.36 | $17.51 | $17.71 | $17.21 | 502,740 | 05-01-2024 |
$17.41 | $17.67 | $17.41 | $17.72 | $17.345 | 1,299,350 | 04-30-2024 |
$17.36 | $17.55 | $17.36 | $17.61 | $17.04 | 4,541,634 | 04-29-2024 |
$18.04 | $18.11 | $18.04 | $18.11 | $18.02 | 388,349 | 04-26-2024 |
$18.13 | $18.06 | $18.13 | $18.145 | $18.02 | 116,525 | 04-25-2024 |
$18.05 | $18.04 | $18.05 | $18.09 | $18.01 | 131,894 | 04-24-2024 |
$18.04 | $17.99 | $18.04 | $18.09 | $17.95 | 181,743 | 04-23-2024 |
$17.96 | $17.97 | $17.96 | $17.99 | $17.9 | 328,603 | 04-22-2024 |
$17.98 | $18.02 | $17.98 | $18.04 | $17.9 | 181,246 | 04-19-2024 |
$18.05 | $18 | $18.05 | $18.08 | $17.91 | 592,892 | 04-18-2024 |
$18.04 | $17.98 | $18.04 | $18.05 | $17.929 | 404,586 | 04-17-2024 |
$17.95 | $17.93 | $17.95 | $18.02 | $17.905 | 559,274 | 04-16-2024 |
$18.02 | $18.04 | $18.02 | $18.09 | $17.95 | 642,393 | 04-15-2024 |
$18.06 | $18.01 | $18.06 | $18.06 | $17.95 | 568,476 | 04-12-2024 |
$18.05 | $18.12 | $18.05 | $18.12 | $18.02 | 92,953 | 04-11-2024 |
$18.02 | $18.08 | $18.02 | $18.08 | $17.95 | 277,526 | 04-10-2024 |
$18.16 | $18.16 | $18.16 | $18.2 | $18.09 | 284,703 | 04-09-2024 |
$18.15 | $18.1 | $18.15 | $18.16 | $18.09 | 240,604 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG Company Name:
MOR Stock Symbol:
NASDAQ Market:
2024-04-30 06:15:05 ET Oddo BHF analyst issues NEUTRAL recommendation for MOR on April 30, 2024 04:35AM ET. MOR was trading at $17.36 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy, 1 - Hold, 1 -...
MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment. My...
– Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – S...